Sudeep Pharma IPO Day One: Check Subscription Status, Financials, And Other Details
Sudeep Pharma IPO has been subscribed 0.03 times or 3% as of 10:09 a.m. on Friday.
Sudeep Pharma Ltd.'s initial public offer was subscribed 0.03 times on first day.
The IPO will include a mix of fresh issues of shares worth Rs 95 crore and an offer for sale of 1 crore shares by existing shareholders. The price band for the issue is set at Rs 563-593 per share.
Sujit Jaysukh Bhayani, Sujeet Jaysukh Bhayani HUF, Shanil Sujit Bhayani and Avani Sujit Bhayani are the promoter selling shareholders offloading stakes in the OFS segment.
ICICI Securities Ltd. and IIFL Capital Services Ltd. are the book-running lead managers for the issue and MUFG Intime India Pvt. will be the registrar of the issue.
The allotment of shares to IPO investors will be done tentatively on Nov. 26. The allotment of shares to IPO investors will be finalised tentatively on Nov. 26, and it will be credited to the demat account will be done on Nov. 27. Sudeep Pharma will list on the BSE and NSE on Nov. 28.
IPO Details
Open date: Nov. 21
Close date: Nov. 25
Price Band: Rs 563-593 per share
Allotment date: Nov. 26
Listing date: Nov. 28
OFS: 1 crore
Fresh issue: Rs 95 crore
Minimum bid: Lot size of 13 shares
Sudeep Pharma Subscription Status
Sudeep Pharma IPO has been subscribed 0.03 times or 3% as of 10:09 a.m. on Friday.
Qualified Institutional Buyers (QIBs): Nil
Non-Institutional Investors (NIIS): 0.05 or 5%.
Retail Individual Investors: 0.04 or 4%
Employee reserved: Nil
Sudeep Pharma GMP Today
Sudeep Pharma's grey market premium was at Rs 122 apiece as of 9:30 a.m. The GMP indicates listing price of 715 apiece, which implies 20.75% upside from the issue price.
Note: GMP does not represent official data and is based on speculation. GMP data sourced from InvestorGain.
Use Of Proceeds
The proceeds from the fresh issue will be utilised for capital expenditure towards procurement of machinery for the company's production line located at Nandesari facility.
Financial Performance
Sudeep Pharma's revenue from operations increased 14% to Rs 459.2 crore in fiscal 2024 from Rs 428.7 crore in fiscal 2023. Profit for the period more than doubled to Rs 133 crore for the financial year ended March 2024 as compared to Rs 62.3 crore in the year-ago period.
As of April 30, 2025, the company's debt pile stood at Rs 110.3 crore.
